Search Patents
  • Patent number: 6417343
    Abstract: Methods for immunocytochemical detection and isolation of RNA.
    Type: Grant
    Filed: October 16, 1997
    Date of Patent: July 9, 2002
    Assignee: New York Medical College
    Inventors: Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan
  • Publication number: 20120195917
    Abstract: The present invention relates to modification of RNA with 5?-cap analogs in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA.
    Type: Application
    Filed: August 3, 2010
    Publication date: August 2, 2012
    Applicant: OCV Intellectual Capital , LLC
    Inventors: Ugur Sahin, Andreas Kuhn, Edward Darzynkiewicz, Jacek Jemielity, Joanna Kowalska
  • Publication number: 20080227088
    Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
    Type: Application
    Filed: May 11, 2005
    Publication date: September 18, 2008
    Inventors: Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
  • Publication number: 20100132726
    Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
    Type: Application
    Filed: February 5, 2010
    Publication date: June 3, 2010
    Applicant: VECTOR TOBACCO, INC.
    Inventors: Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
  • Publication number: 20050042694
    Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
    Type: Application
    Filed: September 29, 2004
    Publication date: February 24, 2005
    Inventors: Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan, Stefan Gruenwald
  • Publication number: 20110214680
    Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
    Type: Application
    Filed: March 28, 2011
    Publication date: September 8, 2011
    Applicants: VECTOR TOBACCO, INC., New York Medical College
    Inventors: Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
  • Patent number: 4801550
    Abstract: The primary and/or secondary structure of nucleic acid as well as its content and molecular weight can be analyzed in solutions by light scatter or fluorescence measurements after treatment with 3 or 4 ring aromatic cations which bind to single-stranded nucleic acids by cooperative association and induce their condensation (collapse). Preparative separation of nucleic acids of different types from the mixtures in the solution is also accomplished by the same principle and techniques wherein each condensed acid is removed from solution and the condensation reversed.
    Type: Grant
    Filed: May 23, 1984
    Date of Patent: January 31, 1989
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Jan Kapuscinski, Zbigniew Darzynkiewicz
  • Patent number: 7662565
    Abstract: Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: February 16, 2010
    Assignee: Vector Tobacco, Inc.
    Inventors: Anthony P. Albino, Ellen D. Jorgensen, Frank Traganos, Zbigniew Darzynkiewicz, Wendy Jin
  • Publication number: 20070269832
    Abstract: The invention provides novel affinity labels for Ser proteases of formula: L-A-X—NH—CH(R?)C(?O)CH2Cl??(I) wherein L, A, X, and R? have any of the values defined in the specification, or salts thereof, as well as compositions comprising such compounds or salts. The composition of the amino acid side-chain (R?) along with the amino acid or amino acid sequence (peptide) of the X component of formula I, affect the target selectivity of the labeled affinity ligand. Utilization of cell permeable, enzyme selective, labeled affinity ligands, provides a precise mechanism for evaluating the current and future status of cell populations.
    Type: Application
    Filed: June 21, 2004
    Publication date: November 22, 2007
    Inventors: David Phelps, Gary Johnson, Brian Lee, Zbigniew Darzynkiewicz, Jerzy Grabarek
  • Publication number: 20030108952
    Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
    Type: Application
    Filed: February 24, 1999
    Publication date: June 12, 2003
    Inventors: ZBIGNIEW DARZYNKIEWICZ, FRANK TRAGANOS, GLORIA JUAN, STEFAN GRUENWALD
  • Patent number: 8519110
    Abstract: Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both in vitro and in vivo. They may be used as inhibitors of cap-dependent translation. Optionally, the boranophosphate or phosphoroselenoate group has a 2?-O or 3?-O-alkyl group, preferably a methyl group, producing analogs called BH3-ARCAs or Se-ARCAs. ARCAs may be modified with ?-, ?-, or ?-boranophosphate or phosphoroselenoate groups.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: August 27, 2013
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Joanna Kowalska, Jacek Jemielity, Edward Darzynkiewicz, Robert E. Rhoads, Maciej Lukaszewicz, Joanna Zuberek
  • Publication number: 20060148023
    Abstract: The invention provides assay methods and reagents useful for evaluating the level of enzyme activities within living cells. Enzyme activity levels within living cells, such as Serine proteases, can be key determinates in assessing; 1) the presence of tumor (cancer) cells, 2) the predictive efficacy of a chemotherapeutic treatment regimen using a particular therapeutic agent or process, 4) the probability of graft rejection or acceptance, and 5) the disease state status of a cell. The identification of the up or down regulation relationships of serine proteases within living cell systems, provides a rapid, yet finely tuned mechanism for predicting the current and future physiological state of these cell populations.
    Type: Application
    Filed: June 21, 2004
    Publication date: July 6, 2006
    Inventors: David Phelps, Gary Johnson, Brian Lee, Zbigniew Darzynkiewicz, Jerzy Grabarek
  • Patent number: 4559309
    Abstract: A process for characterizing sperm motility and viability by staining a sperm sample with Rhodamine 123 and ethidium bromide, and simultaneously measuring the sperm fluorescence emissions at green frequencies 515-575 nm and at red frequencies 600-650 nm, the green counts being correlated with sperm motility and the red counts being correlated with putative dying or dead cells. Additionally, a sample of sperm can be characterized as to type and normality by staining a sample of sperm with acridine orange and simultaneously measuring the sperm fluorescence emissions at green frequencies 515-575 nm and at red frequencies 600-650 nm.
    Type: Grant
    Filed: September 1, 1982
    Date of Patent: December 17, 1985
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Donald P. Evenson, Zbigniew Darzynkiewicz
  • Patent number: 7070943
    Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: July 4, 2006
    Assignee: Becton Dickinson and Company
    Inventors: Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan, Stefan Gruenwald
  • Patent number: 9295717
    Abstract: The present invention relates to modification of RNA with 5?-cap analogs of Formula (1): wherein R1-R6 and n are as described herein, in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA.
    Type: Grant
    Filed: August 3, 2010
    Date of Patent: March 29, 2016
    Assignees: BIONTECH AG, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH, UNIWERSYTET WARSZAWSKI
    Inventors: Ugur Sahin, Andreas Kuhn, Edward Darzynkiewicz, Jacek Jemielity, Joanna Kowalska
  • Publication number: 20050136492
    Abstract: The invention provides assay methods and reagents useful for evaluating the level of enzyme activities within living cells. Enzyme activity levels within living cells, such as caspases and Serine proteases, can be key determinates in assessing; 1) the apoptotic state of a cell, 2) the presence of tumor (cancer) cells, 3) the predictive efficacy of a chemotherapeutic treatment regimen using a particular therapeutic agent or process, 4) the probability of graft rejection or acceptance, identification of the up or down regulation relationships of serine proteases and caspases within living cell systems, provides a rapid, yet finely tuned mechanism for predicting the current and future state of these cell populations, and 5) the disease state status of a cell.
    Type: Application
    Filed: June 21, 2004
    Publication date: June 23, 2005
    Inventors: David Phelps, Gary Johnson, Brian Lee, Zbigniew Darzynkiewicz, Jerzy Grabarek
  • Patent number: 6821740
    Abstract: Methods, reagents, and kits are provided that permit flow cytometric determination of the phosphorylation status of retinoblastoma susceptibility gene protein (pRB) in individual cells. Methods are described that permit the hypophosphorylated, active, form of pRB to be measured either as an absolute quantity or as a proportion of total cellular pRB. Further described are methods that permit pRB phosphorylation status to be correlated with cell cycle phase and with protein components of the cell cycle. Screening of chemical compounds for antiproliferative and antineoplastic activity using the flow cytometric assays is demonstrated. Reagent kits that facilitate the subject methods are also provided.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: November 23, 2004
    Assignee: Becton, Dickinson and Company
    Inventors: Zbigniew Darzynkiewicz, Frank Traganos, Gloria Juan, Stefan Gruenwald
  • Patent number: 5912126
    Abstract: The invention pertains to the field of DNA detection for basic research, medical diagnostic testing, and forensic testing. Methods are provided for end labeling of DNA strands without a denaturation step so that cellular morphology can be better preserved. The DNA strands are first incubated with a halogenated deoxynucleotide triphosphate, such as brominated deoxyuridine triphosphate (BrdUTP), and an enzyme which can catalyze the addition of the halogenated deoxynucleotide to the 3' OH ends of the DNA strand, such as terminal deoxynucleotidyl transferase (TdT). The resulting modified DNA strands are then incubated with a labeled antibody, such as a fluoresceinated monoclonal antibody, that binds specifically to the halogenated deoxynucleotide. The label is then detected, e.g., by flow cytometry. The methods have utility in detecting apotosis, DNA synthesis and/or repair, and as general methods for end labeling DNA.
    Type: Grant
    Filed: October 22, 1996
    Date of Patent: June 15, 1999
    Inventors: Zbigniew Darzynkiewicz, Xun Li, Frank Traganos
  • Publication number: 20060252115
    Abstract: The ability to synthesize capped RNA transcripts in vitro has been of considerable value in a variety of applications. However, one-third to one-half of the caps have, until now, been incorporated in the reverse orientation. Such reverse caps impair the translation of in vitro-synthesized mRNAs. Novel cap analogues, such as P1-3?-deoxy-7-methylguanosine-5? P3-guanosine-5? triphosphate and P1-3?-O,7-dimethylguanosine-5? P3-guanosine-5? triphosphate, have been designed that are incapable of being incorporated into RNA in the reverse orientation. Transcripts produced with SP6 polymerase using “anti-reverse” cap analogues were of the predicted length. Analysis of the transcripts indicated that reverse caps were not formed. The in vitro translational efficiency of transcripts with the novel “anti-reverse” cap analogues was significantly higher than that of transcripts formed with conventional caps.
    Type: Application
    Filed: July 10, 2006
    Publication date: November 9, 2006
    Inventors: Edward Darzynkiewicz, Robert Rhoads, Janusz Stepinski
  • Publication number: 20100233757
    Abstract: New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2?-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are “anti-reverse cap analogs” (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog m7GpppG.
    Type: Application
    Filed: June 19, 2008
    Publication date: September 16, 2010
    Applicant: BOARD OF SUPERVISORS OF LOUSIANA STATE UNIVERSITY
    Inventors: Jacek Jemielity, Ewa M. Grudzien-Nogalska, Joanna Kowalska, Edward Darzynkiewicz, Robert E. Rhoads
Narrow Results

Filter by US Classification